Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1457740 | 0.84 | GAA (0.53) | USP2HSD17B10SMN1; SMN2LMNAHTT | |
| SCHEMBL25980683 | 0.83 | USP2 (0.50) | USP2HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10682349 | 0.82 | TSHR (0.50) | USP2HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25902206 | 0.82 | HTT (0.52) | USP2HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2965222 | 0.82 | USP2 (0.49) | USP2HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5219803 | 0.82 | KDM4E (0.56) | USP2HSD17B10NPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10410179 | 0.80 | KDM4E (0.55) | USP2HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3570164 | 0.79 | ALDH1A1 (0.55) | NPC1RAB9ASMN1; SMN2CREBBPLMNA | |
| SCHEMBL25337733 | 0.78 | USP2 (0.73) | USP2HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL223446 | 0.78 | HSD17B10 (0.55) | USP2HSD17B10NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645753-B2 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1858901-B1 | BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1858901-A1 | BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006094682-A1 | BENZOTHIAZOLE, THIAZOLOPYRIDINE, BENZOOXAZOLE AND OXAZOLOPYRIDINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205718-A1 | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | SSTR5, SSTR1, SSTR2 | USP2 4295/4885HSD17B10 2890/4885NPC1 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.